[HTML][HTML] PET molecular imaging for pathophysiological visualization in Alzheimer's disease
Alzheimer's disease (AD) is the most common dementia worldwide. The exact etiology of AD
is unclear as yet, and no effective treatments are currently available, making AD a …
is unclear as yet, and no effective treatments are currently available, making AD a …
[HTML][HTML] Longitudinal resting-state EEG in amyloid-positive patients along the Alzheimer's disease continuum: considerations for clinical trials
Background To enable successful inclusion of electroencephalography (EEG) outcome
measures in Alzheimer's disease (AD) clinical trials, we retrospectively mapped the …
measures in Alzheimer's disease (AD) clinical trials, we retrospectively mapped the …
[HTML][HTML] A biomarker-validated time scale in years of disease progression has identified early-and late-onset subgroups in sporadic Alzheimer's disease
O Almkvist, A Nordberg - Alzheimer's Research & Therapy, 2023 - Springer
Background It is possible to calculate the number of years to the expected clinical onset
(YECO) of autosomal-dominant Alzheimer's disease (adAD). A similar time scale is lacking …
(YECO) of autosomal-dominant Alzheimer's disease (adAD). A similar time scale is lacking …